Private Wealth Management Group’s Monte Rosa Therapeutics GLUE Stock Holding History

Private Wealth Management Group’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$5.33K	Buy	+447	New	+$7.66K	﹤0.01%	876

Other funds holding GLUE

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Alphabet Inc Mountain View, California $88.3B AUM 46.07% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Private Wealth Management Group's GLUE Position: Q3 2026 in Review

Private Wealth Management Group opened a new position in Monte Rosa Therapeutics (GLUE) in Q3 2026: 447 shares worth $5.33K. The stake represents ﹤0.01% of the portfolio and ranks #876 among its holdings.

57 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.

Private Wealth Management Group held 447 shares of Monte Rosa Therapeutics worth $5.33K as of Q3 2026.
Monte Rosa Therapeutics was a new Private Wealth Management Group position in Q3 2026.
Monte Rosa Therapeutics made up ﹤0.01% of Private Wealth Management Group's portfolio in Q3 2026, its #876 holding.
57 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.

Based on Private Wealth Management Group's 13F filing for Q3 2026, filed 19 Oct 2026.